Skip to main content
Clinical Trials/NCT02460536
NCT02460536
Completed
N/A

Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth

Tel Aviv University1 site in 1 country100 target enrollmentMay 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Anxiety Disorders
Sponsor
Tel Aviv University
Enrollment
100
Locations
1
Primary Endpoint
Change from baseline in anxiety symptoms - the Pediatric Anxiety Rating (PARS)
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Attention biases in threat processing have been assigned a prominent role in the etiology and maintenance of anxiety disorders. Attention Bias Modification Treatment (ABMT) utilizes computer-based protocols to implicitly modify biased attentional patterns in anxious patients. This is a double-blind randomized controlled trial of ABMT for clinically anxious 10-18 year-olds. Participants will be assessed using clinical interviews and parent- and self-rated questionnaires before, in the middle and after twelve sessions of ABMT or control groups, and again at ten-week follow-up. Outcome measures will be anxiety symptoms and depression as measured by gold standard questionnaires as well as structured clinical interviews with youth and their parents. Attentional threat bias, Attentional control and interpretation of ambiguous information will also be measured to explore potential mediators of ABMT's effect on anxiety. The investigators expect the findings to inform pathways to treatments for anxious children and to provide initial information on mechanisms of ABMT efficacy.

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
May 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yair Bar-Haim

Professor of Psychology and Neuroscience, Head School of Psychological Sciences

Tel Aviv University

Eligibility Criteria

Inclusion Criteria

  • Primary diagnosis of GAD, SOP, or SAD.
  • Co-morbid attention deficit hyperactivity disorder (ADHD) or depressive disorders must be treated with medication and stable.
  • Tics or impulse control problems must be treated with medication, stable and cause minimal or no impairment.

Exclusion Criteria

  • To be excluded youth must:
  • meet diagnostic criteria for Organic Mental Disorders, Psychotic Disorders, Pervasive Developmental Disorders, or Mental Retardation.
  • show high likelihood of hurting themselves or others.
  • have not been living with a primary caregiver who is legally able to give consent for the child's participation.
  • be a victim of previously undisclosed abuse requiring investigation or ongoing supervision.
  • be involved currently in another psycho-social treatment.
  • have a serious vision problem that is not corrected with prescription lenses.
  • have a physical disability that interferes with their ability to click a mouse button rapidly and repeatedly.

Outcomes

Primary Outcomes

Change from baseline in anxiety symptoms - the Pediatric Anxiety Rating (PARS)

Time Frame: 4 weeks, 8 weeks, and 18 weeks (follow-up)

The PARS assesses global anxiety severity across different anxiety disorders in youth.

Secondary Outcomes

  • Change from baseline in anxiety related emotional disorders symptoms - Child/Parent Version (SCARED-C/P)(4 weeks, 8 weeks, and 18 weeks (follow-up))

Study Sites (1)

Loading locations...

Similar Trials